[1] |
Jorge B,Beatriz M,Julia M,et al.Chronic kidney disease-mineral and bone disorders: pathogenesis and management[J].Calcif Tissue Int,2020,15.doi:10.1007/s00223-020-00777-1.
|
[2] |
Michael P,Paul D.Current understanding of mineral and bone disorders of chronic kidney disease and the scientific grounds on the use of exogenous parathyroid hormone in its management[J].JBM J Bone Metab,2020,27:1-13.
|
[3] |
Kim HJ,Kang E,Kim Y,et al.The association between soluble klotho and cardiovascular parameters in chronic kidney disease:results from the KNOW-CKD study[J].BMC Nephrol,2018,19:51-59.
|
[4] |
Zhang M, Yan J, Zhu M, et al.Fibroblast growth factor 23 predicts coronary calcification and poor prognosis in patients with chronic kidney disease stages 3-5D[J]. Ann Clin Lab Sci,2015,45: 17-22.
|
[5] |
Albanese I, Khan K, Barratt B, et al. Atherosclerotic calcification: Wnt is the Hint[J]. J Am Heart Assoc,2018,7:e007356.doi:10.1161/JAHA.117.007356.
|
[6] |
Nakahara T, Dweck MR, Narula N, et al. Coronary artery calcification: from mechanism to molecular imaging[J]. JACC Cardiovasc Imaging,2017,10:582-593.
|
[7] |
Voelkl J,Cejka D,Alesutan I.An overview of the mechanisms in vascular calcification during chronic kidney disease[J].Curr Opin Nephrol Hypertens, 2019, 28:289-296.
|
[8] |
Matsumoto T, Takayanagi K, Kojima M, et al.Acute exposure to indoxyl sulfate impairs endotheliumdependent vasorelaxation in rat aorta[J]. Int J Mol Sci,2019,20:338-352.
|
[9] |
Tang WH, Wang CP, Yu TH, et al. Protein-bounded uremic toxin p-cresylsulfate induces vascular permeability alternations[J]. Histochem Cell Biol,2018,149:607-617.
|
[10] |
Rodriguez M,Rodriguez M.Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease[J].F1000Res,2020,9:dio:10.12688/f1000research.22636.1.
|
[11] |
Hernandes FR, Canziani M, Barreto FC, et al. The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: a 12-month follow-up study[J]. PLoS One,2017,12:e0174811.doi:10.137/journal.pone.0174811.
|
[12] |
Roumeliotis S,Dounousi E,Salmas M,et al.Vascular calcification in chronic kidney disease: the role of vitamin K-dependent matrix Gla protein[J].Front Med,2020,7:154-161.
|
[13] |
Ruderman I, Holt SG, Hewitson TD, et al. Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis[J]. Semin Dial,2018,31:487-499.
|
[14] |
Shishkova D,Velikanova E, Sinitsky M, et al.Calcium phosphate bions cause intimal hyperplasia in intact aortas of normolipidemic rats through endothelial injury[J]. Int J Mol Sci. 2019, 20, 5728.doi:10.3390/ijms20225728.
|
[15] |
Bielesz B, Reiter T, Marculescu R, et al. Calcification propensity of serum is independent of excretory renal function[J]. Sci Rep,2017,7:17941.doi:10.1038/s41598-017-18336-4.
|
[16] |
Sheng K, Zhang P, Lin W, et al. Association of matrix Gla protein gene (rs1800801, rs1800802, rs4236) polymorphism with vascular calcifification and atherosclerotic disease: a meta-analysis[J]. Sci Rep,2017,7:8713.doi:10.1038/s41598-017-09328-5.
|
[17] |
Li JS, Li B.Renal injury repair: how about the role of stem cells[J]. Adv Exp Med Biol,2019,1165:661-670.
|
[18] |
Vervoet M,Cozzolino M.Vascular calcification in end-stage renal disease[J].Hemodial Int,2013,17:S17-S21.
|
[19] |
Palmer SC,Mavridis D,Johnson DW,et al.Comparative effectiveness of calcimetic agents for secondary hyperparathyroidism in adults:a systematic review and network meta-analysis[J].Am J Kidney Dis,2020,76:321-330.
|
[20] |
商瑀家,李玉霞,宋佳新,等.钙敏感受体在动脉粥样硬化中的作用研究进展[J].基础医学与临床,2020,40:395-398.
|
[21] |
Parfrey PS,Drueke TB,Block GA,et al.The effects of cinacalcet in older and younger patients on hemodialysis:the evaluation of cinacalcet HCI therapy to lower cardiova-scular events(EVOLVE) trial[J].Clin J Am Soc Nephrol,2015,10:791-199.
|
[22] |
刘志红,李贵森.中国慢性肾脏病矿物质和骨异常诊治指南[M].北京: 人民卫生出版社,2018:49-72.
|